Share Price:

APNASPENAspen Pharmacare Hldgs11630-118 (-1.00%)

Aspen is in a closed period from 1st July 2025 until the publication of the annual results on the JSE SENS platform on the 3rd September 2025.

Regional Overviews

Aspen in Americas

The Americas region is the second largest in terms of sales teams. It features well-recognised domestic and global brands, particularly in the Latin America and Brazil
markets, which drive the majority of sales in these territories. Brazil also has a manufacturing facility which specialises in finished dose form (“FDF”).

Key Countries

Argentina
Brazil
Canada
Chile
Colombia
Mexico

Overview

Brand Therapeutic category
Diprivan

General anaesthetic

Durateston

Testosterone replacement therapy

Lyrica

Anti-epileptic drugs

Meticorten

Corticosteroid

Magnesia Bisurada

Antacid

Ovestin

Estrogen hormone replacement

10
Products
Launched

(2023: 19)

0
Product
Recalls

(2023: 2)

0 %
Average Staff
Turnover

(2023: 27%)

0
Work-related
Facilities

(2023: Nil)

100
Sales
Representatives

(2023: 228)

610
Permanent
Employees

(June 2024)

600
Permanent
Employees

(June 2023)

5
Products
Launched

(2022: 20)

Product
Recalls

(2022: 1)

5 %
Average Staff
Turnover

(2022: 22)

Work-related
Facilities

(2022: Nil)

135
Sales
Representatives

(2022: 235)

250
Permanent
Employees

(June 2022: 714)

Revenue 2024
R’million
2023 (CER)
R’million
Change
%

Commercial Pharmaceuticals

6 677

5 564

20

Prescription

2 832

1 990

42

Injectables

2 395

2 133

12

Over the counter

1 450

1 441

1

Manufacturing

Finished dose form

34

20

70

Total

6 711

5 584

20

Note: Commercial Pharmaceuticals’ revenue is by customer geography.

Contribution to Group revenue (%)
Revenue by segment (%)
Contribution to Group revenue (%)
Revenue by segment (%)
  • Latin America is expected to grow 1,9% CAGR between 2024 and 2028
Source: IQVIA Institute, December 2023.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.